Cargando…

Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye

PURPOSE: To evaluate the safety and efficacy of ophthalmic MIM-D3, a tyrosine kinase TrkA receptor agonist, in patients with dry eye. DESIGN: A prospective, two-center, randomized, double-masked, placebo-controlled Phase 2 study. METHODS: A total of 150 dry eye patients were randomized 1:1:1 to stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meerovitch, Karen, Torkildsen, Gail, Lonsdale, John, Goldfarb, Heidi, Lama, Teresa, Cumberlidge, Garth, Ousler, George W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/ https://www.ncbi.nlm.nih.gov/pubmed/23836957 http://dx.doi.org/10.2147/OPTH.S44688

Ejemplares similares

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
por: Sosne, Gabriel, et al.
Publicado: (2015)

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor, Mike, et al.
Publicado: (2019)

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial
por: Patane, Michael A, et al.
Publicado: (2011)

SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model
por: Petrov, Anton, et al.
Publicado: (2016)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
por: Shrivastava, Saurabh, et al.
Publicado: (2018)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
por: Ousler, George, et al.
Publicado: (2015)

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease
por: Evans, David, et al.
Publicado: (2023)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh, Shizuka
Publicado: (2015)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial
por: Toshida, Hiroshi, et al.
Publicado: (2017)

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study
por: Hori, Yuichi, et al.
Publicado: (2022)

The interblink interval in normal and dry eye subjects
por: Johnston, Patrick R, et al.
Publicado: (2013)

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
por: Wirta, David, et al.
Publicado: (2022)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Effectiveness of hyaluronic acid and arnica extract ophthalmic solution in reducing dry eye symptoms in pediatric population
por: Buzzonetti, Luca, et al.
Publicado: (2022)

Short-term application of diquafosol ophthalmic solution benefits children with dry eye wearing orthokeratology lens
por: Yang, Yuanfang, et al.
Publicado: (2023)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]
Publicado: (2021)

Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
por: Nguyen, Theresa, et al.
Publicado: (2011)

Irrational ophthalmic fixed-dose combinations for dry eye syndrome
por: Kshirsagar, Nilima A, et al.
Publicado: (2022)

Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice
por: Fu, Rongrong, et al.
Publicado: (2019)

Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
por: Ishikawa, Sho, et al.
Publicado: (2023)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

The Forrest Mims engineer's notebook
por: Mims, Forrest M
Publicado: (1992)

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
por: Kim, Chae Eun, et al.
Publicado: (2018)

A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients
por: Takamura, Etsuko, et al.
Publicado: (2012)

The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress
por: Simsek, Cem, et al.
Publicado: (2019)

Improvement of Evaporative Dry Eye With Meibomian Gland Dysfunction in Model Mice by Treatment With Ophthalmic Solution Containing Mineral Oil
por: Watanabe, Keisuke, et al.
Publicado: (2021)

Investigation of extended blinks and interblink intervals in subjects with and without dry eye
por: Rodriguez, John D, et al.
Publicado: (2013)

Automated grading system for evaluation of ocular redness associated with dry eye
por: Rodriguez, John D, et al.
Publicado: (2013)

Tracking Monochloramine Decomposition in MIMS Analysis
por: Roumiguières, Adrien, et al.
Publicado: (2019)

Multiscale Innovative Materials and Structures (MIMS)
por: Barretta, Raffaele, et al.
Publicado: (2021)

Blink patterns and lid-contact times in dry-eye and normal subjects
por: Ousler, George W, et al.
Publicado: (2014)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
por: Inoue, Yasushi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_22tto8p5le8u6jp6m9ege0iji7